Expansion of IL-2-independent tumor-infiltrating lymphocytes through a feeder-free process: a preclinical study for solid tumors [0.03%]
一种无喂养细胞的IL-2非依赖型肿瘤浸润淋巴细胞体外扩增方法及其抗实体瘤效应功能的初步研究
Ying Zhang,Sicheng Du,Rongrui Liu et al.
Ying Zhang et al.
Objective: Conventional tumor-infiltrating lymphocyte (TIL) therapy for solid tumors relies on high-dose interleukin-2 (IL-2) during expansion and post-infusion, and promotes T-cell exhaustion and toxicity. Herein, we dev...
Cancer-immunity cycle-based molecular subtypes in breast cancer predict the response to immune checkpoint inhibitors [0.03%]
基于癌症-免疫循环的乳腺癌分子亚型可预测免疫检查点抑制剂的治疗反应
Di Shao,Tianjian Yu,Yi Xiao et al.
Di Shao et al.
Objective: The cancer-immunity cycle (CIC) outlines key steps of anti-tumor immunity from antigen release to T cell effector function. A comprehensive evaluation of the CIC in patients with breast cancer is lacking, which...
Identification of immune reconstitution and hematopoiesis restoration by scRNA-seq in bone marrow of multiple myeloma patients treated with high-dose melphalan following auto-HSCT [0.03%]
高剂量化疗后自体HSCT治疗多发性骨髓瘤患者免疫重建和造血恢复的单细胞转录组分析
Qian Li,Yaling Wang,Hongfeng Yuan et al.
Qian Li et al.
First-line immunotherapy for advanced HER2-negative gastric cancer: differences between Asian and non-Asian patients [0.03%]
一线免疫治疗晚期HER2阴性胃癌：亚洲和非亚洲患者的区别
Chuanhua Zhao,Sisi Ye,Meng Chen et al.
Chuanhua Zhao et al.
Emerging evidence suggests that the efficacy of immunotherapy in patients with advanced HER2-negative gastric cancer differs between Asian and non-Asian populations. This review examines potential factors contributing to these disparities, ...
Exosomal EPHA2 transfers metastatic potential by stabilizing TGF-βRI and activating the TGF-β/SMAD3 signaling pathway in breast cancer [0.03%]
乳腺癌中 EphA2 标记的外泌体通过稳定 TGF-βⅠ型受体和激活 TGF-β/SMAD3 信号通路转移侵袭性表型
Liming Liu,Yichu Zhang,Xiaoxue Li et al.
Liming Liu et al.
Objective: Intratumoral heterogeneity refers to the presence of distinct subpopulations of cancer cells within a single tumor, which exhibits variations in phenotypic traits, such as proliferation rate, drug sensitivity, ...
Psychological health mediates the association between diet and upper gastrointestinal cancer: a cross-sectional analysis from a large-scale population-based screening project [0.03%]
饮食对上消化道肿瘤的影响存在心理健康的中介作用——一项大规模人群筛查的横断面分析
Yueying Zhang,Shanrui Ma,Xinqing Li et al.
Yueying Zhang et al.
Objective: Upper gastrointestinal (UGI) cancer, including esophageal and gastric cancers, poses a significant health burden. While unhealthy dietary patterns are a recognized risk factor for UGI cancer, the complex interp...
Microbiota-host interaction in colorectal cancer: emerging computational technology, multi-omics integration, and mechanisms [0.03%]
结直肠癌中微生物组与宿主的相互作用：新兴计算技术、多组学整合及机制研究
Yinghong Lu,Jun Yu
Yinghong Lu
Colorectal cancer (CRC) remains a major global health burden with the gut microbiome emerging as a critical contributor to tumor initiation and progression. Advances in high-throughput sequencing have deepened our understanding of host-micr...
Sihan Li,Fashun Li,Jiasheng Tu et al.
Sihan Li et al.
Postbiotics, considered the functional successors of live probiotics, retain most of probiotics' structural and/or bioactive properties, and are key mediators of probiotic-environment interactions. Beyond influencing tumor proliferation, me...
Single-cell and spatial transcriptome analyses reveal tumor immunometabolism in lymph node metastasis of lung cancer [0.03%]
单细胞和空间转录组分析揭示肺癌淋巴结转移的肿瘤免疫代谢特征
Yang Zhang,Wangyang Zhu,Chaoqiang Deng et al.
Yang Zhang et al.
Objective: Progressive metabolic adaptation of tumor cells enables a thriving tumor microenvironment in which immune cells have diminished killing ability. However, whether and how this adaptation plays an active role in ...
Expert consensus on the detection and clinical application of tumor mutational burden [0.03%]
肿瘤突变负荷的检测与临床应用专家共识
Zhenying Guo,Chunwei Xu,Shirong Zhang et al.
Zhenying Guo et al.
As an emerging biomarker, tumor mutational burden (TMB) has attracted increasing attention from clinicians in predicting the efficacy of tumor immunotherapy. Currently, TMB is detected primarily by whole-exome sequencing or targeted panel s...